Trisomy 16 (mosaic)

Overview

Mosaic trisomy 16 occurs when an individual has two distinct cell populations: some cells with the typical two copies of chromosome 16, and others carrying three copies. This chromosomal pattern differs from complete trisomy 16, where every cell contains the extra chromosome. Complete trisomy 16 represents the most frequently identified autosomal trisomy in first-trimester pregnancy losses, yet mosaic forms occasionally allow survival to birth when the proportion of trisomic cells remains low enough to permit development.

The condition arises sporadically, meaning it typically occurs by chance during early embryonic cell division rather than being inherited from parents. When fertilisation produces a normal embryo, subsequent errors in chromosome separation during cell division can generate trisomic cells. If this trisomic cell line persists alongside normal cells, the resulting mosaic pattern develops. The proportion of affected cells varies considerably between individuals, influencing the range and severity of clinical features. In some cases, the extra chromosome 16 may be confined primarily to the placenta rather than the developing baby, a phenomenon termed confined placental mosaicism.

Because the proportion and distribution of trisomic cells differs for each affected individual, mosaic trisomy 16 presents with highly variable clinical outcomes. Some individuals may have minimal health concerns, whilst others experience significant developmental and medical challenges. The rarity of this condition means that long-term outcome data remain limited, though clinical understanding continues to grow.

Symptoms & clinical features

Clinical features of mosaic trisomy 16 vary substantially depending on which tissues carry the trisomic cells and what percentage of cells are affected. Growth restriction often begins before birth, with many affected babies showing lower than expected birth weight. After delivery, growth may continue to lag behind typical developmental curves, and some children remain smaller than their peers throughout childhood.

Developmental delays represent another common feature, though severity varies widely. Some children reach developmental milestones such as sitting, walking and speaking within the typical timeframe, whilst others require additional support and therapies. Intellectual disability may be present but is not universal. Physical characteristics can include minor facial differences, though no single set of features reliably indicates mosaic trisomy 16. Heart defects have been reported in some individuals, though the precise frequency is uncertain due to the rarity of the condition and variable mosaic patterns. When present, these cardiac abnormalities range from minor structural variants that require no intervention to more significant abnormalities needing surgical correction. Kidney and urinary tract anomalies have also been documented in some individuals.

The presence of confined placental mosaicism, where chromosome 16 trisomy affects primarily placental tissue rather than the baby's cells, can still influence pregnancy outcomes. Placentas with high levels of trisomic cells may function less efficiently, potentially leading to intrauterine growth restriction or other pregnancy complications even when the baby carries predominantly normal cells. Each individual's symptom profile reflects their unique mosaic pattern, making generalised predictions challenging without detailed chromosome analysis of multiple tissue types.

Video: Genetics 101

Affected organs

Chromosome 16 contains numerous genes essential for normal development and function across multiple body systems. When present in three copies rather than two, the resulting gene dosage imbalance can affect various organs, though the specific systems involved depend on the distribution of trisomic cells throughout the body.

Growth centres and the cardiovascular system appear most frequently affected. The heart may develop structural differences during early foetal development when cells with the extra chromosome interfere with normal cardiac formation. The kidneys and urinary collecting system also show involvement in some cases, with structural variants that may affect kidney function or increase infection risk. The central nervous system can be impacted, potentially contributing to developmental delays or learning differences, though the degree of neurological involvement correlates with the proportion of brain cells carrying the trisomy. The skeletal system may show minor variations in bone development or structure. When confined placental mosaicism occurs, the placenta itself becomes the primary affected organ, with potential downstream effects on foetal nutrition and growth even when the baby's tissues remain largely unaffected.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

Severity in mosaic trisomy 16 exists along a broad spectrum, ranging from individuals with minimal health impact to those facing significant medical and developmental challenges. The proportion of cells carrying the extra chromosome 16 represents the primary determinant of clinical severity, with higher percentages of trisomic cells generally associated with more pronounced features. However, the distribution of affected cells across different tissues also matters considerably - trisomic cells concentrated in critical organs like the heart or brain may produce more significant effects than the same percentage distributed primarily in other tissues.

Complete trisomy 16, where all cells carry three copies of chromosome 16, invariably results in pregnancy loss, typically during the first trimester. Survival to birth requires mosaicism, meaning that a substantial proportion of cells must maintain the normal two-copy state. Even amongst live-born individuals with mosaic trisomy 16, outcomes vary considerably. Some children experience primarily growth-related concerns with relatively typical cognitive development, whilst others face intellectual disability, multiple congenital anomalies, and ongoing medical needs. Long-term health risks depend on which organ systems are affected and to what degree. Individuals with cardiac abnormalities require ongoing cardiology follow-up, whilst those with kidney variants need monitoring of renal function. The rarity of this condition means that comprehensive natural history data spanning decades remain limited, making long-term prognostic statements difficult. Each case requires individualised assessment and monitoring based on the specific features present.

Genetic causes

Mosaic trisomy 16 results from an error in chromosome distribution during cell division after fertilisation has occurred. Chromosomes normally separate evenly when cells divide, ensuring each daughter cell receives the correct number. Occasionally, chromosome 16 fails to separate properly during mitosis, a process called nondisjunction. When this happens in an early embryonic cell, one daughter cell receives an extra copy of chromosome 16 whilst the other receives only one copy. The cell with a single copy of chromosome 16 (monosomy 16) typically cannot survive, but the trisomic cell may continue dividing alongside the normally developing cells that arose from earlier divisions.

As the embryo grows through repeated cell divisions, descendants of both the normal cells and the trisomic cell form distinct populations within the developing tissues. The earlier the nondisjunction event occurs in embryonic development, the higher the proportion of trisomic cells in the resulting individual. Events occurring very early may produce roughly equal numbers of normal and trisomic cells, whilst errors happening later in development result in smaller trisomic populations. In some cases, the trisomic cell line becomes established primarily or exclusively in placental tissue rather than in the embryo proper, creating confined placental mosaicism.

Chromosome 16 contains around 900 genes contributing to numerous cellular processes throughout the body. Having three copies instead of two disrupts the carefully balanced gene expression required for normal development. Different genes on chromosome 16 control aspects of cardiac development, kidney formation, brain function, and growth regulation. The dosage imbalance created by an extra chromosome copy interferes with these developmental programmes, though the specific effects depend on which tissues carry the trisomy and during which developmental windows those tissues form. Unlike some genetic conditions caused by specific gene mutations, trisomy 16 represents a large-scale chromosomal alteration affecting hundreds of genes simultaneously, contributing to the variable clinical picture.

Inheritance pattern

Mosaic trisomy 16 occurs sporadically, meaning it arises from a random error during early embryonic development rather than being passed down from parents. Parents of a child with mosaic trisomy 16 typically have completely normal chromosomes themselves. The chromosome error occurs after conception, when the fertilised egg or early embryo undergoes cell division. Because this represents a new event in that particular pregnancy, it does not run in families in the way that some genetic conditions do.

The recurrence risk for parents who have had one child with mosaic trisomy 16 remains very low, essentially equivalent to the background population risk. This differs from inherited genetic conditions where carrier parents face a 25% or 50% recurrence risk with each pregnancy. Occasionally, if a parent carries low-level mosaicism in their reproductive cells (germline mosaicism) without being affected themselves, recurrence could theoretically occur, but this situation appears exceedingly rare for trisomy 16. Most families receive reassurance that future pregnancies are very unlikely to be affected by the same chromosomal pattern. Genetic counselling can provide personalised risk assessment and discuss available prenatal testing options for subsequent pregnancies if desired.

Diagnosis & testing

Mosaic trisomy 16 may first be suspected during pregnancy or after birth, depending on when clinical features become apparent. Prenatal diagnosis sometimes occurs when ultrasound scans identify growth restriction, structural anomalies, or placental abnormalities prompting further investigation. Chorionic villus sampling or amniocentesis, procedures that collect foetal cells for chromosome analysis, can detect the presence of trisomic cells. However, because mosaicism means different tissues may have different chromosome patterns, prenatal testing results require careful interpretation. Chorionic villus sampling primarily samples placental tissue, so findings may reflect confined placental mosaicism rather than the baby's chromosome status. Amniocentesis samples cells floating in the amniotic fluid, which derive from foetal tissues, potentially providing a more representative picture of the baby's cell populations.

After birth, diagnosis typically follows investigation of clinical features such as growth restriction, developmental concerns, or congenital anomalies. Chromosome analysis using a blood sample can identify mosaic trisomy 16 when trisomic cells are present in the blood population, though low-level mosaicism might be missed if only a limited number of cells are examined. More sensitive techniques such as fluorescence in situ hybridisation (FISH) or chromosomal microarray analysis can detect lower levels of mosaicism. The choice of testing method depends on clinical circumstances and the level of detail needed. In the UK, clinical genetics services coordinate diagnostic testing when mosaic trisomy 16 is suspected. Testing multiple tissue types may be recommended to determine the extent and distribution of mosaicism throughout the body. Genetic counsellors help families understand test results and their implications for the individual's health and development.

UK care pathway

Individuals with mosaic trisomy 16 typically access care through multiple NHS pathways depending on their specific features. When the condition is diagnosed prenatally, foetal medicine specialists provide ongoing monitoring and counselling. After birth, paediatric teams coordinate initial assessment and management, often involving multiple specialties. If cardiac anomalies are present, paediatric cardiology provides evaluation and treatment planning. Growth concerns may prompt endocrinology input, whilst developmental delays lead to referral to community paediatric services for developmental assessment and therapy coordination.

Clinical genetics services play a central role in confirming the diagnosis, explaining the chromosomal findings, and coordinating appropriate surveillance based on the individual's mosaic pattern. Genetic counsellors help families understand the condition, its implications for the affected individual and other family members, and available support resources. Because mosaic trisomy 16 is rare, care may benefit from discussion amongst specialists familiar with chromosomal disorders. Families can access support through regional genetics centres and may be offered connection with other families affected by similar chromosomal conditions. As the child grows, transitional planning ensures appropriate handover from paediatric to adult services for ongoing monitoring and support.

Related conditions

Several other chromosomal conditions involve mosaicism or trisomy of different chromosomes, sharing some overlapping features with mosaic trisomy 16. Mosaic trisomy 8 and mosaic trisomy 9, for example, also present with variable clinical pictures depending on the proportion and distribution of trisomic cells. These conditions may similarly cause growth restriction, developmental delays, and congenital anomalies, though the specific pattern of features differs based on which chromosome is affected and which genes it carries.

Confined placental mosaicism can occur with various chromosomes beyond chromosome 16, potentially affecting pregnancy outcomes through placental dysfunction even when the baby's chromosomes are normal. Distinguishing between different mosaic trisomies requires chromosome analysis, as clinical features alone do not reliably identify which chromosome is involved. Other conditions causing intrauterine growth restriction and developmental delay, including some single-gene disorders, may be considered in the differential diagnosis until chromosome testing clarifies the underlying cause. Understanding the specific chromosomal abnormality present helps guide appropriate monitoring and management tailored to the known associations of that particular chromosome.

Frequently asked questions

References

1. Benn P. Trisomy 16 and trisomy 16 Mosaicism: a review. American journal of medical genetics. 1998. PMID: 9741470
2. Wolstenholme J. An audit of trisomy 16 in man. Prenatal diagnosis. 1995. PMID: 7784361
3. Post JG, Nijhuis JG. Trisomy 16 confined to the placenta. Prenatal diagnosis. 1992. PMID: 1287635
4. Scott F, Bonifacio M, Sandow R. Rare autosomal trisomies: Important and not so rare. Prenatal diagnosis. 2018. PMID: 29956348
5. Yong PJ, Langlois S, von Dadelszen P. The association between preeclampsia and placental trisomy 16 mosaicism. Prenatal diagnosis. 2006. PMID: 16874839
6. Neiswanger K, Hohler PM, Hively-Thomas LB. Variable outcomes in mosaic trisomy 16: five case reports and literature analysis. Prenatal diagnosis. 2006. PMID: 16557642
7. Zhou L, Li H, Xu C. Characteristics and mechanisms of mosaicism in prenatal diagnosis cases by application of SNP array. Molecular cytogenetics. 2023. PMID: 37400883
8. Su MT, Liang YL, Chen JC. Non-mosaic uniparental trisomy 16 presenting with asplenia syndrome and placental abruption: a case report and literature review. European journal of medical genetics. 2013. PMID: 23395980